OOIR: Observatory of International Research

Papers

(The median citation count of Pulmonary Pharmacology & Therapeutics is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Celebrating the appointment of Mario Cazzola as Honorary Editor of Pulmonary Pharmacology & Therapeutics	42
Improvement of asthma control in adult patients using extrafine inhaled beclomethasone/formoterol fixed combination as maintenance therapy as well as maintenance and reliever therapy – CONTROL study	39
Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)	31
Echocardiographic effects of dupilumab in patients with severe type 2 asthma	28
Shedding light on vitamin D in tuberculosis: A comprehensive review of clinical trials and discrepancies	26
Evaluation of body weight–based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin d	25
Cefepime pharmacokinetics in adult extracorporeal membrane oxygenation patients	22
Editorial Board	20
S1PR1 attenuates pulmonary fibrosis by inhibiting EndMT and improving endothelial barrier function	20
Editorial Board	19
Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation	19
Pharmacokinetic variability of CFTR modulators from standard and alternative regimens	19
Editorial Board	18
Chronic obstructive pulmonary disease and emerging ER stress-related therapeutic targets	17
Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential	16
Synergistic induction of apoptosis in lung cancer cells via TOP2A targeting through combined dihydroartemisinin and chrysin treatment	15
Exploring the role of β2- and β3-adrenergic receptors in cystic fibrosis	15
Anlotinib prove to be a potential therapy for the treatment of pulmonary fibrosis complicated with lung adenocarcinoma	14
Unveiling the protective role of sevoflurane in video-assisted thoracoscopic surgery associated-acute lung injury: Inhibition of ferroptosis	14
FTO regulates the proliferation and apoptosis of pulmonary artery smooth muscle cells through m6A demethylation modification	14
The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study	14
Establishment of multicenter COVID-19 therapeutics preclinical test system in Republic of Korea	13
Triple inhaled therapy in asthma: Beliefs, behaviours and doubts	13
m6A reader IGF2BP2 Mediates Airway Remodeling by Stabilizing Dixdc1 in Asthma Pathogenesis	13
Efficacy and safety of sequential combination therapy for pulmonary arterial hypertension: A meta-analysis of Randomized-Controlled Trials	12

Real-life impact of genotype and severity of lung disease on efficacy of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis	12
Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score	12
Impact on beclometasone dipropionate pharmacokinetics when switching to a low global warming potential propellant in a pressurised metered-dose inhaler	12
Ferroptosis mediates airway epithelial E-cadherin dysfunction in LPS-induced acute lung injury	12
Editorial Board	11
The incidence and prognosis of other iatrogenic immunodeficiency-associated lymphoproliferative disorders of the lung related to methotrexate: A retrospective study	11
Scoping review: The state of research on cryptogenic organizing pneumonia therapeutics	11
Editorial Board	11
Ensifentrine approval: A milestone in the treatment of COPD	11
The era of multiple biologics: Is combination and switching an option in the management of severe asthma?	11
Evaluating the pharmacokinetics of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurised metered-dose inhaler using a low global warming potential propellant	11
Nebulized amphotericin B for preventing exacerbations in allergic bronchopulmonary aspergillosis: A systematic review and meta-analysis	11
Editorial Board	11
Evaluation of the effect of modulator therapies on medication complexity in adult cystic fibrosis patients	10
Editorial Board	10
The wonders of stem cells therapeutic application towards chronic obstructive pulmonary disease	10
Drug-drug interactions in vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor-ivacaftor	9
Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality	9
Pulmonary safety of Staccato alprazolam in healthy participants and participants with mild asthma: Phase 1, randomized, double-blind, placebo-controlled trial	9
Strongyloides venezuelensis-derived venestatin ameliorates asthma pathogenesis by suppressing receptor for advanced glycation end-products-mediated signaling	9
Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot study	9
Bispecific domain antibody attenuates airway hyperresponsiveness and pulmonary inflammation in ovalbumin-lipopolysaccharide induced asthma model by inhibiting IL-23 and TNF-α	9
Remote preconditioning combined with nebulized budesonide alleviate lipopolysaccharide induced acute lung injury via regulating HO-1 and NF-κB in rats	9
β-sitosterol targets glucocorticoid receptor to reduce airway inflammation and remodeling in allergic asthma	8
Tyvaso DPI: Drug-device characteristics and patient clinical considerations	8
Chronic inhaled antibiotic therapy in people with cystic fibrosis with Pseudomonas aeruginosa infection in Germany	8
Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: A real-world database study in Japan	8
Suboptimal peak inspiratory flow rate in dry-powder inhaler users for chronic obstructive pulmonary disease in Korea	8
The efficacy and safety of inhaled antibiotics for pneumonia: A systematic review and meta-analysis	7
Association between pre-ICU aspirin administration and ARDS mortality in the MIMIC-IV database: A cohort study	7
The importance of biomarkers in the treatable-trait approach to chronic airway diseases	7
Efficacy and safety of house dust mite subcutaneous immunotherapy in polysensitized children with allergic asthma	7
Repeated doses of captopril induce airway hyperresponsiveness by modulating the TRPV1 receptor in rats	7
Editorial Board	7
Artificial intelligence in the development of Rentosertib: A novel TNIK inhibitor for idiopathic pulmonary fibrosis – A letter to editor	6
Experimental modeling of pulmonary fibrosis and combined emphysema in mice using repeated doses of bleomycin and cigarette smoke extract	6
Preventive effect of LCZ696 on hypoxic pulmonary hypertension in rats via regulating the PI3K/AKT signaling pathway	6
Advances in novel therapeutics for idiopathic pulmonary fibrosis	6
Effect of daily dosing with tiotropium against methacholine induced bronchoconstriction in asthmatics	6
Inhaled delivery of a lipid nanoparticle encapsulated messenger RNA encoding a ciliary protein for the treatment of primary ciliary dyskinesia	6
SIRT3 alleviates sepsis-induced acute lung injury by inhibiting pyroptosis via regulating the deacetylation of FoxO3a	6
Pulmonary drug delivery for acute respiratory distress syndrome	6
Activating transcription factor 6 in the endothelial context	6
ALDH2 attenuates radiation-induced lung injury by inhibiting ROS and epithelial-mesenchymal transition mediated by the TGF-β1/Smad pathway	6
Icaritin protects against airway inflammation by inhibiting the TLR4/NF-κB pathway in vivo and in vitro	6
Medication use in people with cystic fibrosis before and after modulator therapy	6
Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities	6
Hyperbaric oxygen therapy as an immunomodulatory intervention in COVID-19-induced ARDS: Exploring clinical outcomes and transcriptomic signatures in a randomised controlled trial	5
Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate	5
Effect of roflumilast on airway remodeling in asthmatic mice exposed to or not exposed to cigarette smoke: Comparison with the effect of dexamethasone	5

Effects of elexacaftor-tezacaftor-ivacaftor on daily treatment burden and airflow obstruction in adults with cystic fibrosis	5
Serum exosomal m6A demethylase FTO promotes gefitinib resistance in non-small cell lung cancer by up-regulating FLRT3, PTGIS and SIRPα expression	5
The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting	5
Evodiamine protects against lung ischemia–reperfusion injury by attenuating SYK-associated TLR4/NLRP3 inflammasome activation and ferroptosis-related injury signatures	5
Dexmedetomidine reduces IL-4 and IgE expression through downregulation of theTLR4/NF-κB signaling pathway to alleviate airway hyperresponsiveness in OVA mice	5
Targeting the immunometabolism interface: A novel strategy for IPF therapy	5
Targeted inhibition of IDO1 by Kushenol A enhances radiosensitivity in non-small cell lung cancer	5
Demethyleneberberine alleviates Pseudomonas aeruginosa-induced acute pneumonia by inhibiting the AIM2 inflammasome and oxidative stress	5
Up-regulation of PPAR-γ involved in the therapeutic effect of icariin on cigarette smoke-induced inflammation	4
Clinical efficacy of inhaled corticosteroids in equine asthma: A meta-analysis and number needed to treat	4
The compound artemisinin-hydroxychloroquine ameliorates bleomycin-induced pulmonary fibrosis in rats by inhibiting TGF-β1/Smad2/3 signaling pathway	4
The low global warming potential propellant HFA-152a does not induce bronchoconstriction or impair mucociliary clearance	4
Transcriptional factor MAZ promotes cisplatin-induced DNA damage repair in lung adenocarcinoma by regulating NEIL3	4
Setting expectations with oral selexipag: an expert consensus-based approach on best practices to initiate, dose, titrate, and manage side effects (SEs) in patients with pulmonary arterial hypertensio	4
Impact of statin treatment and exposure on the risk of chronic allograft dysfunction in Chinese lung transplant recipients	4
Nontuberculous mycobacterial (NTM) infections in bronchiectasis patients: A retrospective US registry cohort study	4